RxDoctor Payments Data

Shaylynn Skorka, PA

Physician Assistant · Williamsville, NYNPI 1952073959

Payments from drug & device makers

$4,173in general payments, 2019–2025

Across 200 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$472
  • Eisai Inc.$432
  • Novartis$430
  • GSK$377
  • Johnson & Johnson$355
  • Merck$291
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$4,173100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,173 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$19,730
Medicare patients
138
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZejulaNiraparib Tosylate25$677,424
LynparzaOlaparib47$355,347
LenvimaLenvatinib Mesylate11$261,240
EliquisApixaban14$12,157
PremarinEstrogens, Conjugated11$4,052
Estradiol30$2,313
Dexamethasone52$2,098
Tamoxifen Citrate48$1,851
Megestrol Acetate42$1,326
Clobetasol Propionate39$715
Gabapentin73$682
Fentanyl12$668
Anastrozole27$540
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst41$459
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKZejula$377$677,42425 claims
AstraZenecaLynparza$472$355,34747 claims
Eisai Inc.Lenvima$432$261,24011 claims
PfizerEliquis, Premarin$135$16,20925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →